Located in the heart of Paris, France, Paris Diderot University, previously known as Paris 7, is a prestigious institution of higher education. As one of the successors to the historic University of Paris, which was disbanded in 1970, Paris Diderot University was established by a group of professors from various faculties, including Science, Medicine, and Humanities. The university was renamed after the renowned French philosopher, art critic, and writer Denis Diderot in 1994.

Drugs associated with Université Paris Diderot-Paris 7

KNGOP-1

Target

OOR x μ opioid receptor

Mechanism

OOR antagonists [+1]

Active Org.-

Originator Org.

Atos SE

Active Indication-

Inactive Indication

Neuralgia

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date-

MFH-1

Target

PAF receptor

Mechanism

PAF receptor antagonists

Active Org.-

Originator Org.

Université Paris Diderot-Paris 7

Active Indication-

Inactive Indication

HIV Infections

Drug Highest PhasePending

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Université Paris Diderot-Paris 7

NCT06403865

/ Not yet recruitingNot Applicable

Evaluation en Vie réelle de la qualité de Vie de Personnes Vivant Avec le VIH traité Par cabotégravir et Rilpivirine Par Patient-Reported Outcomes

Context The introduction of the long-acting injectable antiretroviral treatment cabotegravir and rilpivirine into the therapeutic armamentarium for people living with HIV represents a potentially significant evolution in patients' experience of their treatment and pathology. Its effects on the quality of life of PLHIV are explored in this research. In addition, the two-monthly intra-muscular injection regimen also raises questions about the city-to-hospital transition of care for PLHIV, as well as compliance with the therapeutic window.
Main objective To evaluate the effect of switching HIV treatment to CAB+RPV LA on health-related quality of life on the "Treatment Impact" dimension of the PROQOL-HIV questionnaire, 15 months after switching treatment.
Population People living with HIV-1 whose ARV treatment has been changed to an injectable CAB+RPV LA treatment
Study Design Observational study. Inclusion at HIV medical follow-up visit for change of ARV treatment to CAB/RPV.
Self-administered questionnaires at M3, M9 and M15 after change of treatment (first CAB/RPV injection).

Start Date01 May 2024

Sponsor / Collaborator

Université Paris Diderot-Paris 7

[+1]

NCT04356287

/ RecruitingPhase 1/2IIT

Phase I/II Randomized Controlled Trial of Umbilical Cord-derived mesenChymAl stRomal cElls in Systemic Sclerosis

The purpose of this study is to test the safety and efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells (UCMSC) for the treatment of Systemic Sclerosis (SSc).

Start Date05 Jan 2023

Sponsor / Collaborator

Mortimer B. Davis Jewish General Hospital Foundation

[+6]

NCT04631692

/ Active, not recruitingNot Applicable

Impact of Health Literacy Training for General Practitioners and a Consumer Facing Intervention to Improve Colorectal Cancer Screening in Underserved Areas: A Multicentric Cluster Randomized Controlled Trial

The aim of this project is to assess the impact of a health literacy (HL) intervention combining HL and CRC screening training for general practitioners with a short brochure and video targeting eligible patients to increase CRC screening and other secondary outcomes in four underserved geographic areas in France. The investigators will use a two-arm randomized controlled cluster trial at 8 clusters (2 per area) primarily serving underserved populations across 4 geographic areas in France with 32 primary care physicians and 1024 patients recruited.

Start Date01 Oct 2021

Sponsor / Collaborator

Læge Else Poulsens Mindelegat

[+6]

100 Clinical Results associated with Université Paris Diderot-Paris 7

0 Patents (Medical) associated with Université Paris Diderot-Paris 7

27,681

Literatures (Medical) associated with Université Paris Diderot-Paris 7

01 Dec 2025·Journal of Clinical Immunology

2q33 Deletions Underlying Syndromic and Non-syndromic CTLA4 Deficiency

Article

Author: Chelloug, Nora ; Pacault, Mathilde ; Lévy, Jonathan ; Alioua, Najiba ; Lambert, Nathalie ; Rieux-Laucat, Frédéric ; Malan, Valérie ; Schleinitz, Nicolas ; Dupin-Deguine, Delphine ; Merger, Marguerite ; Hanein, Sylvain ; Barlogis, Vincent ; Dehak, Rabha ; Puel, Mathilde ; Bustamante, Jacinta ; Tabet, Anne-Claude ; Stolzenberg, Marie-Claude ; Boussion, Simon ; Hureaux, Marguerite ; Goudet, Claire ; Abou Chahla, Wadih ; Picard, Capucine ; Vély, Frédéric ; Oksenhendler, Eric ; Ouachée-Chardin, Marie ; Treiner, Emmanuel ; Reumaux, Héloïse ; Li, Hailun ; Suarez, Felipe ; Pasquet, Marlène ; Quartier, Pierre ; Rosain, Jérémie ; Brakta, Charlyne ; Luca, Luminita Elena ; Lefèvre, Guillaume ; Farhat, Méryem-Maud ; Neven, Bénédicte

PURPOSECTLA4 deficiency is an inborn error of immunity (IEI) due to heterozygosity for germline loss-of-function variants of the CTLA4 gene located on chromosome 2q33.2. CTLA4 deficiency underlies pleiotropic immune and lymphoproliferation-mediated features with incomplete penetrance. It has been identified in hundreds of patients but copy number variants (CNVs) have been reported in only 12 kindreds, including nine which displayed large 2q33.1-2q33.2 deletions encompassing CTLA4.METHODSWe conducted a nationwide study in France to identify patients with 2q33 deletions encompassing CTLA4. We investigated the clinical and immunological phenotypes and genotypes of these patients.RESULTSWe identified 12 patients across six unrelated kindreds with clinical immunodeficiency. Neurological features were recorded in three patients, including one with syndromic neurodevelopmental disorder. Single-nucleotide polymorphism (SNP) or comparative genomic hybridization (CGH) array analysis, and targeted high-throughput sequencing revealed five different heterozygous 2q33 deletions of 26 kilobases to 7.12 megabases in size and encompassing one to 41 genes. We identified a contiguous gene syndrome (CGS) due to associated KLF7 deficiency in a kindred with a neurodevelopmental phenotype.CONCLUSIONDeletions within the 2q33 region encompassing CTLA4 are rare and not extensively explored, and are probably underdiagnosed in cytogenetic practice. A literature review identified 14 different CGS loci including at least one gene responsible for an IEI. The deletions involved in IEIs should be systematically delimited, to facilitate screening for CGS.

01 May 2025·Cancer Letters

Strategies for early detection and detailed characterization of oral lesions and head and neck squamous cell carcinoma in Fanconi anemia patients

Review

Author: Beddok, Arnaud ; Schramm, Martin ; Velleuer, Eunike ; Peffault de Latour, Regis ; Soulier, Jean ; Genet, Carine ; Martinez, Pierre ; Klijanienko, Jerzy ; Surralles, Jordi ; Thariat, Juliette ; Faivre, Sandrine ; Stoppa Lyonnet, Dominique ; Saintigny, Pierre ; Sicre de Fontbrune, Flore ; Leblanc, Thierry ; Krieg, Christine ; Brakenhoff, Ruud H ; Dalle, Jean-Hugues ; Rigolet, Arnaud ; Dufour, Carlo

Fanconi Anemia (FA) is an inherited disorder associated with profound DNA repair defects, marked by failure to thrive, congenital malformations, progressive bone marrow failure (BMF), and an increased susceptibility to cancer. Clinical manifestations of FA vary widely, with BMF and clonal evolution predominantly affecting younger individuals, while adults are more frequently presenting with solid tumors. Individuals with FA are at a 500-fold increased risk of developing head and neck squamous cell carcinoma (HNSCC), which tends to appear at a median age of 30 years, often at advanced stages with only a 57 % two-year survival rate. The DNA repair deficiency prohibits the use of cisplatin and radiation therapy, limiting the treatment options for FA patients. Given the critical importance of early HNSCC detection in FA patients, innovative and less invasive diagnostic techniques are needed. This review discusses the role of brush biopsy-based cytology combined with molecular and morphometric analyses, as well as next-generation sequencing. Cytology alone demonstrated significant potential for detecting high-grade oral epithelial dysplasia and early-stage HNSCC, achieving sensitivities and specificities of 97.7 % and 84.5 %, respectively. Such techniques allow for stringent surveillance of the oral cavity in FA patients, essential given the aggressive nature of HNSCC in FA and the limited treatment options. In the absence of oral mucosal lesions, a six-month follow-up is recommended. For oral lesions persisting beyond three weeks, diagnostic evaluation is warranted, with clinical follow-up every three months for low-grade dysplasia and treatment of high-grade dysplasia. Integrating modern diagnostic tools within a comprehensive screening framework, alongside patient participation, is essential for personalized care, improved surveillance, and developing preventive measures to enhance FA patient care.

01 May 2025·Anesthesia & Analgesia

Assisted Fluid Management and Sublingual Microvascular Flow During High-Risk Abdominal Surgery: A Randomized Controlled Trial

Article

Author: Van der Linden, Philippe ; Alexander, Brenton ; Flick, Moritz ; Joosten, Alexandre ; Coeckelenbergh, Sean ; Duranteau, Jacques ; Soucy-Proulx, Maxim ; Grogan, Tristan ; Vicaut, Eric ; Rinehart, Joseph ; Entzeroth, Marguerite ; Vincent, Jean-Louis ; Cannesson, Maxime

BACKGROUND:Implementation of goal-directed fluid therapy (GDFT) protocols remains low. Protocol compliance among anesthesiologists tends to be suboptimal owing to the high workload and the attention required for implementation. The assisted fluid management (AFM) system is a novel decision support tool designed to help clinicians apply GDFT protocols. This system predicts fluid responsiveness better than anesthesia practitioners do and achieves higher stroke volume (SV) and cardiac index values during surgery. We tested the hypothesis that an AFM-guided GDFT strategy would also be associated with better sublingual microvascular flow compared to a standard GDFT strategy.METHODS:This bicenter, parallel, 2-arm, prospective, randomized controlled, patient and assessor-blinded, superiority study considered for inclusion all consecutive patients undergoing high-risk abdominal surgery who required an arterial catheter and uncalibrated SV monitoring. Patients having standard GDFT received manual titration of fluid challenges to optimize SV while patients having an AFM-guided GDFT strategy received fluid challenges based on recommendations from the AFM software. In all patients, fluid challenges were standardized and titrated per 250 mL and vasopressors were administered to maintain a mean arterial pressure >70 mm Hg. The primary outcome (average of each patient’s intraoperative microvascular flow index (MFI) across 4 intraoperative time points) was analyzed using a Mann-Whitney U test and the treatment effect was estimated with a median difference between groups with a 95% confidence interval estimated using the bootstrap percentile method (with 1000 replications). Secondary outcomes included SV, cardiac index, total amount of fluid, other microcirculatory variables, and postoperative lactate.RESULTS:A total of 86 patients were enrolled over a 7-month period. The primary outcome was significantly higher in patients with AFM (median [Q1–Q3]: 2.89 [2.84–2.94]) versus those having standard GDFT (2.59 [2.38–2.78] points, median difference 0.30; 95% confidence interval [CI], 0.19–0.49; P < .001). Cardiac index and SVI were higher (3.2 ± 0.5 vs 2.7 ± 0.7 l.min–1.m–2; P = .001 and 42 [35–47] vs 36 [32–43] mL.m–2; P = .018) and arterial lactate concentration was lower at the end of the surgery in patients having AFM-guided GDFT (2.1 [1.5–3.1] vs 2.9 [2.1–3.9] mmol.L–1; P = .026) than patients having standard GDFT strategy. Patients having AFM received a higher fluid volume but 3 times less norepinephrine than those receiving standard GDFT (P < .001).CONCLUSIONS:Use of an AFM-guided GDFT strategy resulted in higher sublingual microvascular flow during surgery compared to use of a standard GDFT strategy. Future trials are necessary to make conclusive recommendations that will change clinical practice.

100 Deals associated with Université Paris Diderot-Paris 7

100 Translational Medicine associated with Université Paris Diderot-Paris 7

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 13 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

KNGOP-1 ( OOR x μ opioid receptor )	Neuralgia More	Discontinued
MFH-1 ( PAF receptor )	HIV Infections More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis